Prescient Therapeutics Ltd banner

Intrinsic Value

The intrinsic value of Prescient Therapeutics Ltd (PTX) under the Base Case is 0.01 AUD per share. Compared with the current market price of 0.065 AUD, the stock appears Overvalued by 84% .

The intrinsic value is calculated using valuation multiples.

Do our valuations actually work? See backtest results .

PTX Intrinsic Value
AU$0.01
Overvaluation 84%
Intrinsic Value
Price AU$0.065

PTX is valued in line with its history. A premium of this size has been typical over the past 5 years.

Monitor PTX
Get notified when the price drops
Track Buy Zone
20% below Intrinsic Value AU$0.01
Get notified when the price drops into your buy zone
Current Price AU$0.07
Intrinsic Value AU$0.01
Margin of Safety 20% AU$0.01
Or choose another margin of safety
0% below Intrinsic Value
10% below Intrinsic Value
30% below Intrinsic Value
40% below Intrinsic Value
50% below Intrinsic Value
Custom
Alternatives to PTX

Fundamental Analysis

What Prescient Therapeutics Does

Biotechnology Health Care

Prescient Therapeutics Ltd is a clinical-stage biotechnology company focused on cancer treatments. It develops cell-based and targeted therapies designed to help the immune system attack cancer cells or make tumors more vulnerable to treatment. Its work is aimed at cancers with strong unmet medical need, especially where standard treatments have limited effect or resistance can build over time.

Headquarters
Australia AU
IPO date
Dec 19, 1986
Read the full company overview
View Company Overview
Financials
Efficiency

Earnings Waterfall
Prescient Therapeutics Ltd

Wall St Price Targets

Capital Returns

Competitive Landscape

What is the Intrinsic Value of one PTX stock?

The intrinsic value for Prescient Therapeutics Ltd (PTX) under the Base Case is 0.01 AUD.

Is PTX stock undervalued or overvalued?

Compared with the current market price of 0.065 AUD, the stock appears Overvalued by 84% .

Back to Top